Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Simons M, Simmer F, Bulten J, Ligtenberg MJ, Hollema H, van Vliet S, de Voer RM, Kamping EJ, van Essen DF, Ylstra B, Schwartz LE, Wang Y, Massuger LF, Nagtegaal ID, Kurman RJ.

Mod Pathol. 2019 Nov 6. doi: 10.1038/s41379-019-0401-y. [Epub ahead of print]

PMID:
31695154
2.

Clinical practice variation and overtreatment risk in women with abnormal cervical cytology in the Netherlands; two-step versus see-and-treat approach.

Loopik DL, Siebers AG, Melchers WJG, Massuger LFAG, Bekkers RLM.

Am J Obstet Gynecol. 2019 Oct 21. pii: S0002-9378(19)31221-9. doi: 10.1016/j.ajog.2019.10.004. [Epub ahead of print]

PMID:
31647895
3.

RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues.

van den Heuvel CNAM, Loopik DL, Ebisch RMF, Elmelik D, Andralojc KM, Huynen M, Bulten J, Bekkers RLM, Massuger LFAG, Melchers WJG, Siebers AG, Leenders WPJ.

Mod Pathol. 2019 Sep 19. doi: 10.1038/s41379-019-0369-7. [Epub ahead of print]

PMID:
31537894
4.

Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: a prospective multicentre cohort study.

Reijnen C, van der Putten LJM, Bulten J, Snijders MPLM, Küsters-Vandevelde HVN, Sweegers S, Vos MC, van der Wurff AAM, Ligtenberg MJL, Massuger LFAG, Eijkelenboom A, Pijnenborg JMA.

Int J Cancer. 2019 Sep 15. doi: 10.1002/ijc.32686. [Epub ahead of print]

PMID:
31523803
5.

Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study.

Reijnen C, Visser NC, Kasius JC, Boll D, Geomini PM, Ngo H, Van Hamont D, Pijlman BM, Vos MC, Bulten J, Snijders MP, Massuger LF, Pijnenborg JM.

J Gynecol Oncol. 2019 Sep;30(5):e70. doi: 10.3802/jgo.2019.30.e70.

6.

Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival.

Vos MC, van Tilborg A, Brands WJ, Boll D, van Hamont D, van der Putten H, Pijlman B, van der Wurff AAM, van Kuppevelt TH, Massuger LFAG.

Cancer Biomark. 2019;25(3):233-241. doi: 10.3233/CBM-181826.

PMID:
31282404
7.

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.

Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AG, Verwaal VJ, Van de Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Retèl VP.

J Clin Oncol. 2019 Aug 10;37(23):2041-2050. doi: 10.1200/JCO.19.00594. Epub 2019 Jun 28.

PMID:
31251694
8.

Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Reijnen C, IntHout J, Massuger LFAG, Strobbe F, Küsters-Vandevelde HVN, Haldorsen IS, Snijders MPLM, Pijnenborg JMA.

Oncologist. 2019 Sep;24(9):e880-e890. doi: 10.1634/theoncologist.2019-0117. Epub 2019 Jun 11.

PMID:
31186375
9.

Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study.

van Weelden WJ, Fasmer KE, Tangen IL, IntHout J, Abbink K, van Herwaarden AE, Krakstad C, Massuger LFAG, Haldorsen IS, Pijnenborg JMA.

BMC Cancer. 2019 Jun 7;19(1):547. doi: 10.1186/s12885-019-5770-6.

10.

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review.

van Weelden WJ, Massuger LFAG; ENITEC, Pijnenborg JMA, Romano A.

Front Oncol. 2019 May 7;9:359. doi: 10.3389/fonc.2019.00359. eCollection 2019.

11.

Peptide-mediated delivery of therapeutic mRNA in ovarian cancer.

van den Brand D, Gorris MAJ, van Asbeck AH, Palmen E, Ebisch I, Dolstra H, Hällbrink M, Massuger LFAG, Brock R.

Eur J Pharm Biopharm. 2019 Aug;141:180-190. doi: 10.1016/j.ejpb.2019.05.014. Epub 2019 May 16.

PMID:
31103743
12.

Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.

Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, Brucker SY, Kwon JS, McAlpine JN, Pijnenborg JMA.

Gynecol Oncol. 2019 Jul;154(1):124-130. doi: 10.1016/j.ygyno.2019.03.097. Epub 2019 May 15.

PMID:
31103324
13.

Experience with HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the Netherlands.

Polman NJ, de Haan Y, Veldhuijzen NJ, Heideman DAM, de Vet HCW, Meijer CJLM, Massuger LFAG, van Kemenade FJ, Berkhof J.

Prev Med. 2019 Aug;125:5-11. doi: 10.1016/j.ypmed.2019.04.025. Epub 2019 May 2.

PMID:
31054907
14.

Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.

Visser NCM, van der Putten LJM, van Egerschot A, Van de Vijver KK, Santacana M, Bronsert P, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Krakstad C, Tangen IL, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Hausnerova J, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Trovik J, Amant F, Massuger LFAG, Bulten J, Pijnenborg JMA.

Hum Pathol. 2019 Jul;89:90-98. doi: 10.1016/j.humpath.2019.04.014. Epub 2019 May 3.

PMID:
31054899
15.

Poor outcome in hypoxic endometrial carcinoma is related to vascular density.

Reijnen C, van Weelden WJ, Arts MSJP, Peters JP, Rijken PF, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Reques A, Mancebo G, Krakstad C, Trovik J, Haldorsen IS, Huvila J, Koskas M, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Küsters-Vandevelde HVN, Matias-Guiu X, Amant F; ENITEC-consortium, Massuger LFAG, Bussink J, Pijnenborg JMA.

Br J Cancer. 2019 May;120(11):1037-1044. doi: 10.1038/s41416-019-0461-2. Epub 2019 Apr 23.

PMID:
31011231
16.

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

Grant DJ, Manichaikul A, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Moorman PG, Peres LC, Peters ES, Schwartz AG, Terry PD, Wang XQ, Keku TO, Hoyo C, Berchuck A, Sandler DP, Taylor JA, O'Brien KM, Velez Edwards DR, Edwards TL, Beeghly-Fadiel A, Wentzensen N, Pearce CL, Wu AH, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Modugno F, Ness R, Moysich K, Rossing MA, Doherty JA, Sellers TA, Permuth-Way JB, Monteiro AN, Levine DA, Setiawan VW, Haiman CA, LeMarchand L, Wilkens LR, Karlan BY, Menon U, Ramus S, Gayther S, Gentry-Maharaj A, Terry KL, Cramer DW, Goode EL, Larson MC, Kaufmann SH, Cannioto R, Odunsi K, Etter JL, Huang RY, Bernardini MQ, Tone AA, May T, Goodman MT, Thompson PJ, Carney ME, Tworoger SS, Poole EM, Lambrechts D, Vergote I, Vanderstichele A, Van Nieuwenhuysen E, Anton-Culver H, Ziogas A, Brenton JD, Bjorge L, Salvensen HB, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Moffitt M, Cook L, Le ND, Brooks-Wilson A, Kelemen LE, Pharoah PDP, Song H, Campbell I, Eccles D, DeFazio A, Kennedy CJ, Schildkraut JM.

Cancer Med. 2019 May;8(5):2503-2513. doi: 10.1002/cam4.1996. Epub 2019 Apr 18.

17.

Post-Colposcopy Management and Progression Predictors of Biopsy-Proven CIN1 in Women Under 25 Years.

Loopik DL, Bekkers RLM, Massuger LFAG, Melchers WJG, Siebers AG, Bentley JR.

J Obstet Gynaecol Can. 2019 Mar;41(3):292-299. doi: 10.1016/j.jogc.2018.06.021. Epub 2018 Oct 27.

PMID:
30786980
18.

Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma.

Vos MC, Hollemans E, van der Steen SCHA, van Kuppevelt TH, van der Wurff AAM, Massuger LFAG.

Int J Gynecol Pathol. 2019 Feb 7. doi: 10.1097/PGP.0000000000000587. [Epub ahead of print]

PMID:
30741846
19.

Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites.

Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger LFAG, De Vries IJM.

Front Immunol. 2019 Jan 11;9:3156. doi: 10.3389/fimmu.2018.03156. eCollection 2018.

20.

Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial.

Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, Meijer CJLM, Quint WGV, Snijders PJF, Massuger LFAG, van Kemenade FJ, Berkhof J.

Lancet Oncol. 2019 Feb;20(2):229-238. doi: 10.1016/S1470-2045(18)30763-0. Epub 2019 Jan 15.

PMID:
30658933
21.

Is there uniformity in definitions and treatment of gestational trophoblastic disease in Europe?

Frijstein MM, Lok CAR, Coulter J, van Trommel NE, Ten Kate-Booij MJ, Golfier F, Seckl MJ, Massuger LFAG.

Int J Gynecol Cancer. 2019 Jan;29(1):108-112. doi: 10.1136/ijgc-2018-000028.

PMID:
30640691
22.

A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary.

Simons M, Bolhuis T, De Haan AF, Bruggink AH, Bulten J, Massuger LF, Nagtegaal ID.

Virchows Arch. 2019 Mar;474(3):289-296. doi: 10.1007/s00428-018-2504-0. Epub 2019 Jan 10.

23.

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.

Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, Li B, Ye F, Berchuck A, Anton-Culver H, Banerjee S, Benitez J, Bjørge L, Brenton JD, Butzow R, Campbell IG, Chang-Claude J, Chen K, Cook LS, Cramer DW, deFazio A, Dennis J, Doherty JA, Dörk T, Eccles DM, Edwards DV, Fasching PA, Fortner RT, Gayther SA, Giles GG, Glasspool RM, Goode EL, Goodman MT, Gronwald J, Harris HR, Heitz F, Hildebrandt MA, Høgdall E, Høgdall CK, Huntsman DG, Kar SP, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Koushik A, Lambrechts D, Le ND, Levine DA, Massuger LF, Matsuo K, May T, McNeish IA, Menon U, Modugno F, Monteiro AN, Moorman PG, Moysich KB, Ness RB, Nevanlinna H, Olsson H, Onland-Moret NC, Park SK, Paul J, Pearce CL, Pejovic T, Phelan CM, Pike MC, Ramus SJ, Riboli E, Rodriguez-Antona C, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Shan K, Siddiqui N, Sieh W, Stampfer MJ, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Tworoger SS, Tyrer JP, Webb PM, Wentzensen N, White E, Willett WC, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J.

Cancer Res. 2019 Feb 1;79(3):505-517. doi: 10.1158/0008-5472.CAN-18-2726. Epub 2018 Dec 17.

PMID:
30559148
24.

Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report.

Roelofsen T, Wefers C, Gorris MAJ, Textor JC, Massuger LFAG, de Vries IJM, van Altena AM.

Front Oncol. 2018 Nov 29;8:562. doi: 10.3389/fonc.2018.00562. eCollection 2018.

25.

Factors influencing decision-making around opportunistic salpingectomy: a nationwide survey.

Steenbeek MP, van Lieshout LAM, Aarts JWM, Piek JMJ, Coppus SFPJ, Massuger LFAG, Hermens RPMG, de Hullu JA.

J Gynecol Oncol. 2019 Jan;30(1):e2. doi: 10.3802/jgo.2019.30.e2. Epub 2018 Apr 30.

26.

Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.

Frijstein MM, Lok CAR, van Trommel NE, Ten Kate-Booij MJ, Massuger LFAG, van Werkhoven E, Kaur B, Tidy JA, Sarwar N, Golfier F, Winter MC, Hancock BW, Seckl MJ; all the contributors to the ISSTD PSTT/ETT database.

Gynecol Oncol. 2019 Feb;152(2):361-367. doi: 10.1016/j.ygyno.2018.11.015. Epub 2018 Nov 22.

PMID:
30473257
27.

Vulvar Paget disease: A national retrospective cohort study.

van der Linden M, Oonk MHM, van Doorn HC, Bulten J, van Dorst EBL, Fons G, Lok CAR, van Poelgeest MIE, Slangen BMF, Massuger LFAG, de Hullu JA.

J Am Acad Dermatol. 2019 Oct;81(4):956-962. doi: 10.1016/j.jaad.2018.11.016. Epub 2018 Nov 17.

PMID:
30458205
28.

Quantification of Leydig cells and stromal hyperplasia in the postmenopausal ovary of women with endometrial carcinoma.

Reijnen C, Küsters-Vandevelde HVN, Abbink K, Zusterzeel PLM, van Herwaarden AE, van der Laak JAWM, Massuger LFAG, Snijders MPLM, Pijnenborg JMA, Bulten J.

Hum Pathol. 2019 Mar;85:119-127. doi: 10.1016/j.humpath.2018.10.022. Epub 2018 Nov 11.

PMID:
30428390
29.

Justifying conservative management of CIN2 in women younger than 25 years - A population-based study.

Loopik DL, Bekkers RLM, Massuger LFAG, Melchers WJG, Siebers AG, Bentley J.

Gynecol Oncol. 2019 Jan;152(1):82-86. doi: 10.1016/j.ygyno.2018.10.038. Epub 2018 Nov 7.

PMID:
30413339
30.

Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.

Ebisch RMF, Ketelaars PJW, van der Sanden WMH, Schmeink CE, Lenselink CH, Siebers AG, Massuger LFAG, Melchers WJG, Bekkers RLM.

PLoS One. 2018 Oct 24;13(10):e0206219. doi: 10.1371/journal.pone.0206219. eCollection 2018.

31.

Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.

Leeman A, Ebisch RMF, Kasius A, Bosgraaf RP, Jenkins D, van de Sandt MM, de Strooper LMA, Heideman DAM, Snijders PJF, Massuger LFAG, Bekkers RLM, Meijer CJLM, van Kemenade FJ, Quint WGV, Melchers WJG.

Gynecol Oncol. 2018 Nov;151(2):311-318. doi: 10.1016/j.ygyno.2018.09.006. Epub 2018 Sep 13.

PMID:
30219239
32.

Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer.

Snoek BC, Verlaat W, Babion I, Novianti PW, van de Wiel MA, Wilting SM, van Trommel NE, Bleeker MCG, Massuger LFAG, Melchers WJG, Sie D, Heideman DAM, Snijders PJF, Meijer CJLM, Steenbergen RDM.

Int J Cancer. 2019 Jan 15;144(2):372-379. doi: 10.1002/ijc.31855. Epub 2018 Nov 4.

33.

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.

Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, Lu K, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeney LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubiński J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A; Ovarian Cancer Association Consortium.

Int J Mol Sci. 2018 Aug 21;19(9). pii: E2473. doi: 10.3390/ijms19092473.

34.

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.

Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Hogdall CK, Høgdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Jung AY, Karlan BY, Kellar M, Kiemeney LA, Kiong Lim B, Kjaer SK, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lele S, Lester J, Levine DA, Li Z, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LFAG, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Odunsi K, Olson SH, Orlow I, Orsulic S, Paul J, Pejovic T, Pelttari LM, Permuth JB, Pike MC, Poole EM, Rosen B, Rossing MA, Rothstein JH, Runnebaum IB, Rzepecka IK, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tworoger SS, van Altena AM, Vergote I, Vestrheim Thomsen LC, Vierkant RA, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu AH, Wu X, Xiang YB, Yang H, Zheng W, Ziogas A, Lee AW, Pearce CL, Berchuck A, Schildkraut JM, Ramus SJ, Monteiro ANA, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PDP, Goode EL, Phelan CM.

PLoS One. 2018 Jul 6;13(7):e0197561. doi: 10.1371/journal.pone.0197561. eCollection 2018.

35.

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.

Wefers C, Schreibelt G, Massuger LFAG, de Vries IJM, Torensma R.

Front Immunol. 2018 Jun 19;9:1412. doi: 10.3389/fimmu.2018.01412. eCollection 2018.

36.

Stop routine screening for associated malignancies in cutaneous noninvasive vulvar Paget disease?

van der Linden M, Schuurman MS, Bulten J, Massuger LFAG, IntHout J, van der Aa MA, de Hullu JA.

Br J Dermatol. 2018 Dec;179(6):1315-1321. doi: 10.1111/bjd.16894. Epub 2018 Sep 9.

PMID:
29923188
37.

siRNA in ovarian cancer - Delivery strategies and targets for therapy.

van den Brand D, Mertens V, Massuger LFAG, Brock R.

J Control Release. 2018 Aug 10;283:45-58. doi: 10.1016/j.jconrel.2018.05.012. Epub 2018 May 16. Review.

38.

[Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].

Steenbeek MP, Bulten J, Hoogerbrugge N, Massuger LFAG, Pijnenborg JMA, de Hullu JA.

Ned Tijdschr Geneeskd. 2018;162:D2337. Dutch.

PMID:
29676714
39.

Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples.

Verlaat W, Snoek BC, Heideman DAM, Wilting SM, Snijders PJF, Novianti PW, van Splunter AP, Peeters CFW, van Trommel NE, Massuger LFAG, Bekkers RLM, Melchers WJG, van Kemenade FJ, Berkhof J, van de Wiel MA, Meijer CJLM, Steenbergen RDM.

Clin Cancer Res. 2018 Jul 15;24(14):3456-3464. doi: 10.1158/1078-0432.CCR-17-3615. Epub 2018 Apr 9.

40.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.

Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Rzepecka IK, Webb PM; Ovarian Cancer Association Consortium.

Br J Cancer. 2018 Apr;118(8):1123-1129. doi: 10.1038/s41416-018-0011-3. Epub 2018 Mar 20.

41.

Vulvar cancer: Two pathways with different localization and prognosis.

Hinten F, Molijn A, Eckhardt L, Massuger LFAG, Quint W, Bult P, Bulten J, Melchers WJG, de Hullu JA.

Gynecol Oncol. 2018 May;149(2):310-317. doi: 10.1016/j.ygyno.2018.03.003. Epub 2018 Mar 16.

PMID:
29555332
42.

HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.

Abbink K, Zusterzeel PL, Geurts-Moespot AJ, Herwaarden AEV, Pijnenborg JM, Sweep FC, Massuger LF.

Tumour Biol. 2018 Feb;40(2):1010428318757103. doi: 10.1177/1010428318757103.

PMID:
29463191
43.

Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer.

Visser NCM, van der Wurff AAM, Pijnenborg JMA, Massuger LFAG, Bulten J, Nagtegaal ID.

Virchows Arch. 2018 Mar;472(3):407-413. doi: 10.1007/s00428-017-2289-6. Epub 2018 Feb 9.

44.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS.

N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.

45.

Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System.

Wefers C, Duiveman-de Boer T, Zusterzeel PLM, Massuger LFAG, Fuchs D, Torensma R, Wheelock CE, de Vries IJM.

Int J Mol Sci. 2018 Jan 17;19(1). pii: E273. doi: 10.3390/ijms19010273.

46.

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.

van der Putten LJM, Visser NCM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Werner HMJ, Amant F, Massuger LFAG, Pijnenborg JMA.

Int J Gynecol Cancer. 2018 Mar;28(3):514-523. doi: 10.1097/IGC.0000000000001187.

PMID:
29324536
47.

Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.

Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, Greene MH, Slangen BFM, van Beurden M, Massuger LFAG, Hoogerbrugge N, de Hullu JA.

Cancer. 2018 Mar 1;124(5):952-959. doi: 10.1002/cncr.31211. Epub 2018 Jan 9.

48.

Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers.

Arts-de Jong M, van Westerop LL, Hoogerbrugge N, Massuger LF, Maas AH, van Beek MH, de Hullu JA.

Maturitas. 2018 Feb;108:13-17. doi: 10.1016/j.maturitas.2017.11.002. Epub 2017 Nov 3.

PMID:
29290209
49.

A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.

Harmsen MG, Steenbeek MP, Hoogerbrugge N, van Doorn HC, Gaarenstroom KN, Vos MC, Massuger LFAG, de Hullu JA, Hermens RPMG.

Health Expect. 2018 Jun;21(3):659-667. doi: 10.1111/hex.12661. Epub 2017 Dec 27.

50.

Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.

Timmermans M, Schuurman MS, Ho VKY, Massuger LF, Nijman HW, van Gorp T, Sonke GS, Kruitwagen RFPM, van der Aa MA.

Gynecol Oncol. 2018 Jan;148(1):56-61. doi: 10.1016/j.ygyno.2017.11.009. Epub 2017 Nov 10.

PMID:
29129391

Supplemental Content

Loading ...
Support Center